Sistema de Salut de Catalunya
Institut Català de la Salut
[Peñalva G] Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. [Cantón R] Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. [Pérez-Rodríguez MT] Hospital Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur), Vigo (Pontevedra), Spain. Healthcare Associated Infections Study Group (GEIRAS), Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), Madrid, Spain. [González-López JJ] Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Antimicrobial Resistance and Mechanisms of Action Study Group (GEMARA), Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), Madrid, Spain. [Rodríguez-Baño J] Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Institute of Biomedicine of Seville (IBiS), University Hospital Virgen Macarena, CSIC/Universidad de Sevilla, Departamento de Medicina, Universidad de Sevilla, Seville, Spain. [del Barrio-Tofiño E, Kirkegaard-Biosca C] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-03-21T12:21:57Z
2025-03-21T12:21:57Z
2025-04
Antimicrobial resistance; Burden; Hospital
Resistència antimicrobiana; Càrrega; Hospital
Resistencia antimicrobiana; Carga; Hospital
Background Assessing the burden of antimicrobial resistance is essential to determine the magnitude of this problem and to set its priority. We aimed to estimate the burden of disease caused by multidrug-resistant microorganisms (MDRO) in hospitalised patients in Spain. Methods Three prospective nationwide studies were conducted in 2018, 2019 and 2023. All patients with a new diagnosis of infection with any of 10 selected MDROs plus Clostridioides difficile during the study period (one week in 2018 and 2019 and two weeks in 2023) were included. Patient demographic, and clinical outcomes were analysed, including incidence, crude all-cause 30-day mortality and years of life lost (YLL). These results were used to calculate weighted and seasonally adjusted annual estimates for the whole country. Findings In total, 82, 133 and 130 centres participated in the study in 2018, 2019 and 2023, respectively, recording a total of 907, 1392 and 2351 MDRO infections, representing a weighted incidence density of 3.54 (95% CI 2.92–4.17), 5.01 (3.95–6.07), and 4.41 (3.55–5.27) cases/1000 stays, respectively. A total of 161, 198 and 352 patients died with an MDRO infection, representing a weighted incidence density of 0.46 (0.16–0.76), 0.43 (0.17–0.69), and 0.62 (0.52–0.72) deaths/1000 stays, respectively. Based on these data, a nationwide occurrence of 155,294 MDRO infections (95% CI 127,928–182,569) with 20,065 deaths (6938–32,958) was estimated for 2018, 210,451 MDRO infections (165,963–254,975) with 17,982 deaths (7071–28,700) for 2019, and 173,653 MDRO infections (139,814–207258) with 24,582 deaths (20,461–28,796) for 2023. Interpretation The burden of disease caused by MDRO infections among hospitalised patients in Spain is very high and remains stable over the study period. National actions to combat bacterial resistance need to be intensified.
The management costs of this study were funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Researchers have participated voluntarily and none of the investigators received funding for conducting the study.
Article
Published version
English
Medicaments antifúngics - Ús terapèutic; Microorganismes - Resistència als medicaments; Hospitals - Pacients; Assistència sanitària - Cost; Malalties bacterianes - Tractament; PHENOMENA AND PROCESSES::Microbiological Phenomena::Bacterial Physiological Phenomena::Drug Resistance, Bacterial; HEALTH CARE::Health Care Facilities, Manpower, and Services::Health Facilities::Hospitals; HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost of Illness; DISEASES::Bacterial Infections and Mycoses::Bacterial Infections; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents; Other subheadings::Other subheadings::/therapeutic use; FENÓMENOS Y PROCESOS::fenómenos microbiológicos::fenómenos fisiológicos bacterianos::farmacorresistencia bacteriana; ATENCIÓN DE SALUD::instalaciones, servicios y personal de asistencia sanitaria::centros sanitarios::hospitales; ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::coste de las enfermedades; ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos; Otros calificadores::Otros calificadores::/uso terapéutico
Elsevier
The Lancet Regional Health - Europe;51
https://doi.org/10.1016/j.lanepe.2025.101220
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]
